id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-3178-0006,FDA,FDA-2019-E-3178,Determination of Regulatory Review Period for Purposes of Patent Extension; Omegaven,Notice,Determinations,2023-11-01T04:00:00Z,2023,11,2023-11-01T04:00:00Z,2024-01-03T04:59:59Z,2023-11-01T14:53:17Z,2023-24124,0,0,09000064861bdf63
FDA-2019-E-3178-0005,FDA,FDA-2019-E-3178,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-10-19T04:00:00Z,2023,10,2023-10-19T04:00:00Z,,2023-10-19T20:50:38Z,,0,0,090000648610f105